Sophia Genetics reported a 16% year-over-year revenue increase to $18.3 million for Q2 2025, driven by growth outside biopharma sectors. The company expanded its multimodal AI collaboration with AstraZeneca to analyze breast cancer data, generating real-world evidence in North America and Europe. The deal represents Sophia’s largest contract to date, with expected revenues commencing in Q4. The firm also reported increased customer base and anticipates biopharma growth returning to positive territory in upcoming quarters.